Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 48,379 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Withdrawn Phase 1 Interventional

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

NCT05894447
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Beyond Progression (BBP)

NCT01740258
View directory record Official record
Conditions
Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions
Radiation Therapy, Temozolomide, Bevacizumab
Radiation · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

NCT02063958
View directory record Official record
Conditions
Cancer
Interventions
SNX-5422
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Stanford, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Traditional Balance vs Vibrotactile Feedback Training for Vestibular Rehabilitation

NCT01672658
View directory record Official record
Conditions
Traumatic Brain Injury, Vestibular Deficits
Interventions
Sensory Kinetics Balance System, Traditional Vestibular Rehabilitation
Device · Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

NCT01386528
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Intervention to Promote Resilience to Traumatic Stress During Pregnancy

NCT04992767
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Pregnancy Related
Interventions
Sunnyside, SunnysideFlex
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Cemiplimab in Adults With Cervical Cancer

NCT03257267
View directory record Official record
Conditions
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Interventions
Cemiplimab, Investigator Choice (IC) Chemotherapy
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 25, 2026, 5:43 PM EDT
Active, not recruiting Not applicable Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092
View directory record Official record
Conditions
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Not listed Not applicable Interventional

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

NCT06276036
View directory record Official record
Conditions
Cytopenia
Interventions
Identification of specific markers
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
1 Year to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Not yet recruiting Phase 4 Interventional

An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab

NCT07832136
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
veligrotrug (LUMVOA™)
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Newport Beach, California • Sarasota, Florida • East Weymouth, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Effects of Oropharyngeal Strengthening on Dysphagia in Patients Post-stroke

NCT02322411
View directory record Official record
Conditions
Stroke
Interventions
Isometric Progressive Resistance Oropharyngeal Therapy, Compensatory approaches
Device · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 25, 2026, 5:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Music-Based Interventions, Aging, Alzheimer's Disease

NCT06152211
View directory record Official record
Conditions
Speech Perception, Anxiety, Social Behavior
Interventions
Choir, Group Music Listening
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Active, not recruiting No phase listed Observational

Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography

NCT04772911
View directory record Official record
Conditions
Vascular Stains
Interventions
Optical Coherence Tomography (OCT)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Irvine, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed No phase listed Observational

Myofascial Pain and Central Sensitization

NCT04929171
View directory record Official record
Conditions
Myofascial Pain, Physical Therapy
Interventions
Physical Therapy
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual Care, Dalbavancin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Limited English Proficiency Virtual Family-Centered Rounds

NCT05917899
View directory record Official record
Conditions
Pediatric Disorder
Interventions
Virtual Family-Centered Rounds
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

Building Connections

NCT07091032
View directory record Official record
Conditions
Cancer Colorectal, Cancer Cervix, Depression, Anxiety, Obesity
Interventions
Treatment as Usual, Building Connections Intervention
Other · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Coaches Activating Reaching and Engaging Patients

NCT03856463
View directory record Official record
Conditions
Cancer, End-of-Life
Interventions
Lay Navigator Intervention, Usual Care
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Lifestyle Changes Through Exercise and Nutrition

NCT02863887
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Weight loss intervention
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 25, 2026, 5:43 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

NCT05163314
View directory record Official record
Conditions
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 56 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 25, 2026, 5:43 PM EDT